Advancing Women’s Health Starts
with Groundbreaking Research
We combine cutting-edge technology with clinical expertise to develop innovative testing solutions. Our research efforts are dedicated to improving women's lives through earlier risk assessment, more accurate diagnoses, and personalized care strategies through rigorous scientific investigation.
OvaSuiteSM: A Comprehensive Portfolio
of Non-invasive Ovarian Care Solutions
Planned for Clinical Management
- For adnexal masses initially evaluated as indeterminate or benign
- Negative Predictive Value of over 99%1
- Longitudinal monitoring feature to help providers track risk over time
Planned for Surgical Management
- For adnexal masses that are planned for surgery
- Ova1® has a sensitivity of over 96% with clinical assessment2
- Biomarkers (including CA-125), menopausal status, and ultrasound for a personalized risk score
Ova1Plus is a reflex process: Ova1® is performed first. If an intermediate risk is detected, Overa® is automatically performed.
A recent study indicates that using OvaWatch could have led to a potential3:
overall reduction in avoidable adnexal mass surgeries
reduction of surgical referrals among asymptomatic patients
reduction of surgical referrals among premenopausal patients
Learn More About Aspira
Learn More About Aspira
PRECAUTION:
OVAWATCH IS INTENDED FOR USE AS A NON-INVASIVE TEST TO ASSESS THE RISK OF OVARIAN CANCER FOR WOMEN WITH ADNEXAL MASSES, EVALUATED BY INITIAL CLINICAL ASSESSMENT (ICA) AS INDETERMINATE OR BENIGN. IN CONJUNCTION WITH IMAGING (ULTRASOUND AND/OR CT) AND CLINICAL ASSESSMENT, THIS TEST WILL SUPPORT PHYSICIANS IN MAKING INFORMED CLINICAL DECISIONS IN THE MANAGEMENT OF WOMEN WITH ADNEXAL MASSES. THE TEST IS NOT INTENDED AS A SCREENING TEST OR A STAND-ALONE DIAGNOSTIC ASSAY.
OVA1 AND OVERA SHOULD NOT BE USED WITHOUT AN INDEPENDENT CLINICAL AND IMAGING EVALUATION AND IS NOT INTENDED TO BE A SCREENING TEST OR TO DETERMINE WHETHER A PATIENT SHOULD PROCEED TO SURGERY. INCORRECT USE CARRIES THE RISK OF UNNECESSARY TESTING, SURGERY, AND/OR DELAYED DIAGNOSIS.
*In cases of an intermediate Ova1® result, the FDA-cleared Overa® reflex is performed to increase specificity